Explore Telmisartan dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator data.
Telmisartan is a blood-pressure drug (an ARB) approved as Micardis that also lightly activates PPAR-γ, which is why it's sourced in research for metabolic and fat-loss studies. It ships as tablets or a research-grade powder.
The primary mechanism is competitive AT1 receptor antagonism, blocking the vasoconstrictor and aldosterone-releasing effects of angiotensin II — the standard ARB-class pharmacology that drives the blood-pressure-lowering and cardiovascular-protective effects. The PPAR-γ partial-agonist activity (Benson et al., Hypertension 2004) is roughly 25–30% of the maximal activity of full PPAR-γ agonists like rosiglitazone, and operates at the clinically used 40–80mg telmisartan doses — distinguishing telmisartan from other ARBs that lack this activity.[2] The PPAR-γ component is the mechanistic basis for telmisartan's reported effects on insulin sensitivity, visceral fat distribution, and lipid handling beyond what would be expected from blood-pressure-lowering alone.
ONTARGET (Yusuf et al., NEJM 2008) — the largest ARB cardiovascular outcomes trial — established that telmisartan was non-inferior to ramipril for cardiovascular outcomes in high-cardiovascular-risk patients and supported the 2009 FDA label addition for cardiovascular risk reduction.[3] TRANSCEND (Yusuf et al., Lancet 2008) extended the evidence to ACE-inhibitor-intolerant patients.[4] Smaller mechanistic trials have characterised telmisartan's metabolic effects: improved insulin sensitivity, reduced visceral adipose tissue, and modest weight-loss signals at the standard 40–80mg doses, separate from blood-pressure effects.[5] The clinical significance of the PPAR-γ activity for any metabolic indication remains debated; telmisartan is not approved for any metabolic, body-composition, or fat-loss indication.
FDA-approved as Micardis for hypertension (1998) and for cardiovascular risk reduction in adults ≥55 at high cardiovascular risk who cannot tolerate ACE inhibitors (2009). Not approved for any metabolic, fat-loss, or body-composition indication despite off-label use for those purposes. Research-grade material elsewhere.
Telmisartan has a reported half-life of ~24 hours. The pharmacokinetic reference models an interval of once daily; this is not a measured community cadence or a dosing recommendation. A roughly day-long half-life makes once-daily dosing effective for 24-hour blood-pressure control, building to a steady level over a few days. Pharmacokinetic source: FDA label (Micardis). It is catalogued under Other Peptides on WPA.
The WPA community has not yet logged enough Telmisartan calculator sessions to publish dose, vial size, or bacteriostatic water distributions for it. This page therefore covers what is known about the compound itself; the usage charts fill in as researchers run the calculator.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.